Investors
A MESSAGE FROM OUR CEO
”We are very grateful to those helping with the ADVANCE trial and to all of our shareholders who continue to give us their support.”
-
February 20, 2025 RegulatorySynAct’s Nomination Committee proposes Jeppe Ragnar Andersen to the Board
-
February 18, 2025 RegulatorySynAct Pharma Year-end Report 2024
-
January 31, 2025 RegulatoryChange in number of shares and votes in SynAct Pharma AB
The interim report for Q4 2024 was published on February 18, 2025, at 07.30 CEST.